Reportlinker Adds ERPR Positive HER2 Negative Breast Cancer: Clinical Insights From a US Oncologists' Survey

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0487244/ERPR-Positive-HER2-Negative-Breast-Cancer-Clinical-Insights-from-a-US-Oncologists-Survey.html

ER/PR Positive HER2neu Negative Metastatic Breast Cancer

Patient specific case scenarios presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.

Patient case highlights:

In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choose…

In a 60-year-old woman with diabetes, hypertension, renal insufficiency, and chronic obstructive pulmonary disease who found a lump in her breast and tests revealed metastatic lesions in ribs, spine, and femur initially treated with…

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

Table of Contents

Executive Summary5

Chapter 1: Introduction9

Table 1. Treatment Options in Metastatic Breast Cancer9

Chapter 2: Respondent Demographics11

Table 2. Eligibility Criteria for Survey Participation11

Figure 2.1 Gender of Survey Respondents11

Figure 2.2 Years since Medical School Graduation12

Figure 2.3 Practice Settings12

Figure 2.4 Practices in NCI Cancer Centers13

Figure 2.5 Geographic Settings13

Figure 2.6 Survey Respondents by State's Breast Cancer Mortality14

Figure 2.7 Number of Physicians in Practice Groups15

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen15

Chapter 3: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer16

Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer16

Figure 3.116

Other than analgesics, treatment of patient's hip pain with ER/PR positive HER2/neu negative metastatic breast cancer17

Figure 3.217

Treatment with ER/PR positive HER2/neu negative metastatic breast cancer17

Figure 3.317

Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer18

Figure 3.418

Factors Influencing Treatment Choice with ER/PR positive HER2/neu Negative Metastatic Breast Cancer19

Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer20

Figure 3.520

Chapter 4: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer with Comorbidities21

Confidence managing patient with metastatic breast cancer with multiple comorbidities21

Figure 4.121

Barriers to managing patient, metastatic breast cancer with multiple comorbidities22

Figure 4.222

Treatment in addition to the aromatase inhibitor for patient's metastatic breast cancer with multiple comorbidities24

Figure 4.324

Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities25

Figure 4.425

Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities26

Figure 4.526

Chapter 5: Summary28

Appendix A: Survey Instrument29

Companies mentioned

Celgene, Pfizer, Astra Zeneca, Genentech/Roche, Novartis, Eisai, Eli Lilly, Abbott Labs, Sanofi-aventis, GlaxoSmithKline

To order this report:

:

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.